In his recent State of the Union address, President Obama committed to creating a “cancer moonshoot” initiative the aim of which is to fund research, discovery and development of new cures for cancer through substantial various new funding programs.
The initiative has once again propelled immunotherapy into the spotlight, a broad terms used to describe approaches to treat and cure cancer that directly target the human immune system.
At the core of many immunotherapeutic approaches is the use of immuno-stimulatory cytokines, like interleukin-2 (IL- 2), which have the ability to mediate tumor regression in melanoma and other malignancies.
Also called T-cell growth factor, IL-2 is an immunoregulatory lymphoid factor which can promote T-cell-dependent immune responses. IL-2 was first used therapeutically to boost immune responses in patients with invasive cancer or advanced HIV disease.
IL-2, in particular, was discovered early on to be able to produce significant tumor responses in chemotherapy-refractory diseases and that donor-derived T-cell infusions are able to illicit disease responses in patients who had relapsed following allogeneic hematopoietic stem cell transplant.
Lately, IL-2 has met the spotlight again due to its involvement in tumor infiltrating lymphocyte (TIL) technology.
TIL involves expanding lymphocytes extracted from a patient’s tumor and expanded before being infused back into the patient. IL-2 plays a key role in the expansion and immunosuppressive effect of these cells.
Significant clinical responses have been observed in 50% of patients so far.
Recent literature that has appeared within the last year also describes the current state-of-the-art of the use of IL-2 for the treatment of metastatic melanoma. One such publication is from the lab of Dr. Jennifer Vargo at MD Anderson’s Cancer Center, and can be accessed here.
Akron has been supporting immunotherapy advances by providing a sophisticated network of cytokines, at grades which include fully-documented GMP quality, for various indications.
In particular, our IL-2 is fully documented and backed by an extensive dossier of data including extended stability and functionality documentation. You can get more information on our GMP-grade IL-2 here.
With IL-2 at the forefront, Akron also supplies a variety of other growth factors the roles of which are to enhance immunological response to clients that range from clinical-stage entities to research and development labs and academic institutions.
Akron has the experience and understanding of the complexity involved in the development of a new immunotherapy: from raw and ancillary material supply to logistics, through to regulatory support throughout the process, out know-how extends beyond the lab bench.